SCHEMBL5469474

SCHEMBL5469474

CCOC(=O)CCn1cc(C=C2C(=O)Nc3ccccc32)c2ccccc21

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 3/20 0.63
NTRK1 P04629 1/20 0.61
MAP3K5 Q99683 1/20 0.61
KMT2A Q03164 8/20 0.57
MEN1 O00255 6/20 0.57
MAPT P10636 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
NPSR1 Q6W5P4 2/20 0.57
POLB P06746 2/20 0.57
CRHBP P24387 1/20 0.56
CRHR2 Q13324 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.55
SYK P43405 4/20 0.54
FCER2 P06734 2/20 0.53
CREBBP Q92793 1/20 0.53
PTGS2 P35354 1/20 0.49
ALDH1A1 P00352 1/20 0.48
PSEN1 P49768 1/20 0.48
PSEN2 P49810 1/20 0.48
APH1B Q8WW43 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5469468 1.00 DHFR (0.63) DHFRNTRK1MAP3K5KMT2AMEN1
SCHEMBL5482789 0.90 KMT2A (0.66) DHFRNTRK1MAP3K5KMT2AMEN1
SCHEMBL5482792 0.90 KMT2A (0.66) DHFRNTRK1MAP3K5KMT2AMEN1
SCHEMBL5476102 0.86 DHFR (0.70) DHFRNTRK1MAP3K5KMT2AMEN1
SCHEMBL5476100 0.86 DHFR (0.70) DHFRNTRK1MAP3K5KMT2AMEN1
SCHEMBL5817698 0.85 KMT2A (0.58) DHFRNTRK1MAP3K5KMT2AMEN1
SCHEMBL5468658 0.85 NTRK1 (0.72) DHFRNTRK1MAP3K5KMT2AMEN1
SCHEMBL14448834 0.85 NTRK1 (0.72) DHFRNTRK1MAP3K5KMT2AMEN1
SCHEMBL5468662 0.85 NTRK1 (0.72) DHFRNTRK1MAP3K5KMT2AMEN1
SCHEMBL5816953 0.84 KMT2A (0.56) DHFRNTRK1MAP3K5KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US claimed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP claimed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO claimed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed
WO-2006105796-A1 NOVEL INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2006-10-12 WO disclosed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP disclosed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167488-A1 Novel therapeutic use MAG, PMP22, MYT1 DHFR 3147/4885NTRK1 175/4885MAP3K5 3047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.